- Home
- GNLX vs XGN Comparison
GNLX vs XGN Comparison
Compare GNLX & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- XGN
- Stock Information
- Founded
- GNLX 2001
- XGN 2002
- Country
- GNLX United States
- XGN United States
- Employees
- GNLX N/A
- XGN N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- XGN Medical Specialities
- Sector
- GNLX Health Care
- XGN Health Care
- Exchange
- GNLX Nasdaq
- XGN Nasdaq
- Market Cap
- GNLX 128.0M
- XGN 138.3M
- IPO Year
- GNLX 2023
- XGN 2019
- Fundamental
- Price
- GNLX $3.78
- XGN $10.10
- Analyst Decision
- GNLX Strong Buy
- XGN Strong Buy
- Analyst Count
- GNLX 5
- XGN 4
- Target Price
- GNLX $16.20
- XGN $11.75
- AVG Volume (30 Days)
- GNLX 89.3K
- XGN 387.3K
- Earning Date
- GNLX 08-07-2025
- XGN 07-29-2025
- Dividend Yield
- GNLX N/A
- XGN N/A
- EPS Growth
- GNLX N/A
- XGN N/A
- EPS
- GNLX N/A
- XGN N/A
- Revenue
- GNLX N/A
- XGN $58,862,000.00
- Revenue This Year
- GNLX N/A
- XGN $19.68
- Revenue Next Year
- GNLX N/A
- XGN $13.68
- P/E Ratio
- GNLX N/A
- XGN N/A
- Revenue Growth
- GNLX N/A
- XGN 3.89
- 52 Week Low
- GNLX $1.95
- XGN $2.38
- 52 Week High
- GNLX $5.89
- XGN $10.34
- Technical
- Relative Strength Index (RSI)
- GNLX 62.02
- XGN 77.40
- Support Level
- GNLX $3.26
- XGN $9.39
- Resistance Level
- GNLX $3.50
- XGN $9.90
- Average True Range (ATR)
- GNLX 0.24
- XGN 0.44
- MACD
- GNLX 0.01
- XGN 0.03
- Stochastic Oscillator
- GNLX 99.47
- XGN 88.52
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.